/stocks — the workspaceLOADING
All HUMA SEC filings, by type → · Earnings date & implied move · Search inside filings
Humacyte, Inc. (HUMA) is a biological products, (no diagnostic substances) company. Piotroski F-Score 3/8. 5 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-11-11 from HUMA's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
What’s behind HUMA’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
No sensitivity grid: free cash flow is not positive, so the DCF gives no value at any growth or discount rate.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from HUMA’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on HUMA plus an auto-SWOT — built from HUMA's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate HUMA using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has HUMA been issuing shares? Offering history →
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as HUMA tagged it: revenue us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
None of the 5 estimators could run on HUMA's filings.
One estimator is a point estimate, not a range, so no band and no valuation label are published for HUMA. Below is everything that was checked, so the refusal can be read rather than taken on trust.
Nothing produced a value.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for HUMA, so sector medians could not fill the gaps.
Every refusal recorded for HUMA → · How often we decline, and why →
No lawmaker has disclosed a trade in HUMA under the STOCK Act.
No tracked institution reported a position in HUMA in the latest 13F round.
Every registered fund files its complete portfolio with the SEC. These weights come from those filings, so each one carries the period it describes. Holdings are quarterly and filed in arrears — the figures below are as of 2026-06-30, not today.
| Fund | Weight | As of |
|---|---|---|
| VTI Vanguard Total Stock Market ETF | <0.01% | 2026-06-30 |
| ITOT iShares Core S&P Total US Stock Market ETF | <0.01% | 2026-06-30 |
Drawn from 39 large US equity funds we scan, not every fund in existence, so a missing fund means we do not scan it rather than that it holds none. Holdings are joined to tickers by issuer name, which does not resolve every position; what that misses is published.
Projected from HUMA's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentHUMA files or announces.
HUMA has sold off after 6 of its last 8 earnings reports.
Each figure is one earnings reaction — how much HUMA moved from the closing price the day before a report to the close the day after. Based on its last 8 reports.
Large earnings reactions have been common.
HUMA has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+41.7% and -27.6%).
A more typical earnings reaction has been approximately ±18.9%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-08-12 | -22.5% |
| 2026-03-19 | -26.1% |
| 2025-11-12 | -7.0% |
| 2025-08-11 | -27.6% |
| 2025-05-13 | +41.7% |
| 2025-03-28 | -15.2% |
| 2024-11-08 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| +4.9% |
| 2024-08-13 | -9.1% |
Head office: Durham, North Carolina, United States · the company’s charter and its head office are in different states.
Source: the cover page of Humacyte, Inc.’s 10-Q filed 2026-08-12, on EDGAR. Filings checked 2026-10-21. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
Of 2 sales in the last ~6 months, 2 were filed with the Rule 10b5-1 box checked, set up in advance under a written trading plan.
| Jones Keith AnthonyDirector | BUY | $6K | view → |
| Jones Keith AnthonyDirector | BUY | $7K | view → |
| Jones Keith AnthonyDirector | BUY | $18K | view → |
| Parikh Shamik JChief Medical Officer | SELLplan | $41K | view → |
| Sander Dale A.CFO and Chief Corp. Dev. Off | SELLplan | $41K | view → |
| Constantino Michael T.Director | BUY | $10K | view → |
| Sebelius KathleenDirector | BUY | $50K | view → |
2 of the 2 checks that ran found nothing new for HUMA. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.